Researchers developing new potential therapies for cystic fibrosis (CF) can now apply for a new competition that will give them 1 year of free laboratory space and support at Bakar Labs, as published in a press release. The competition called “Golden Ticket” is a collaboration between the Cystic Fibrosis Foundation and Bakar Labs in Berkeley, California.

“As part of our relentless pursuit of a cure, we are dedicated to investing in early stage science”, said Martin Mense, PhD, senior vice president of drug discovery and director of the Cystic Fibrosis Foundation Therapeutics Lab. “We know that to make progress toward our bold mission to cure CF, we need to attract bold, like-minded researchers.”

With this competition, researchers who are in the very early stages of translational research and life science entrepreneurs will have a chance to gain support.

Read more about experimental treatments for CF

“This Golden Ticket Competition provides the incredible resources of both the Foundation and Bakar Labs to help great minds bring ambitious ideas closer to reality,” Dr. Mense said. “We are constantly exploring new approaches to drive research, to bring tomorrow’s breakthrough technologies into [CF] research today.”

The competition will start on May 2nd and continue through to May 30, 2022. Researchers working on new technologies in gene editing, gene delivery, and gene therapy with a potential application in CF are eligible. On July 20, 2022, there will be a pitch day event during which finalists will present their project to a panel of judges from the Cystic Fibrosis Foundation and Bakar Labs.

CF is an autosomal recessive multisystem disorder. There are a number of symptomatic and disease-modifying treatments available but none of these can cure CF. There are also a number of experimental treatments that are currently in development.

Reference

Cystic Fibrosis Foundation launches inaugural golden ticket competition to find the next genetic therapies for CF. News release. Cystic Fibrosis Foundation; April 18, 2022.